EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.32 USD | +0.08% |
|
-0.44% | +12.22% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 6.56B | Sales 2025 * | 7.2B | Capitalization | 51.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.62B | Net income 2025 * | 1.86B | EV / Sales 2024 * | 7.57 x |
| Net cash position 2024 * | 1.68B | Net cash position 2025 * | 2.84B | EV / Sales 2025 * | 6.74 x |
| P/E ratio 2024 * |
32.1
x | P/E ratio 2025 * |
27.7
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | +0.22% | ||
| 1 week | -1.37% | ||
| Current month | +0.69% | ||
| 1 month | -8.04% | ||
| 3 months | -0.94% | ||
| 6 months | +27.11% | ||
| Current year | +11.80% |
1 week
83.50
86.95
1 month
83.5093.11
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
13.02131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
| Chairman | 71 | 99-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Director/Board Member | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 44 M€ | +0.89% | - | |
| 2.34% | 18 M€ | +3.01% | - | |
| 2.13% | 6 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 85.68 | +0.50% | 159 656 |
| 24-05-03 | 85.25 | +0.22% | 2,327,197 |
| 24-05-02 | 85.06 | +0.90% | 1,942,855 |
| 24-05-01 | 84.3 | -0.44% | 2,203,110 |
| 24-04-30 | 84.67 | -1.49% | 3,097,564 |
Delayed Quote Nyse, May 03, 2024 at 04:00 pm EDT
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-05-07
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
85.25
USD
Average target price
95.24
USD
Spread / Average Target
+11.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.80% | 51.37B | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| -0.91% | 62.38B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B | |
| +26.14% | 31.88B | |
| +18.24% | 24.39B |
- Stock Market
- Equities
- EW Stock